BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Information letter regarding Methergin® (methylergometrine maleate): Withdrawal of Methergin® oral solution from the market, safety information for the use of Methergin® solution for injection

Active substance: methylergometrine maleate

The pharmaceutical manufacturer issues information on the withdrawal of Methergin® oral solution from the market due to case reports of adverse drug reactions in connection with medication errors/misuse in neonates. In addition, safety information on the administration of the Methergin® solution for injection is given.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 57KB, File is accessible